Company Atossa Genetics Inc Nasdaq
Equities
US04962H1005
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Shu-Chih Chen
FOU | Founder | 62 | 30/11/08 |
Steven Quay
CEO | Chief Executive Officer | 73 | 30/11/08 |
Heather Rees
DFI | Director of Finance/CFO | 51 | 31/12/16 |
Arezoo Mirad
CTO | Chief Tech/Sci/R&D Officer | - | 12-03 |
Richard Graydon
CTO | Chief Tech/Sci/R&D Officer | - | 24/10/22 |
Delly Behen
ADM | Chief Administrative Officer | - | 31/12/13 |
Eric van Zanten
IRC | Investor Relations Contact | - | 06/12/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 73 | 30/11/08 |
Director/Board Member | 66 | 28/02/14 | |
H. Remmel
BRD | Director/Board Member | 72 | 31/01/12 |
Shu-Chih Chen
FOU | Founder | 62 | 30/11/08 |
Stephen Galli
BRD | Director/Board Member | 77 | 30/06/11 |
Jonathan Finn
BRD | Director/Board Member | 50 | 11-07 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 127,077,462 | 125,684,004 ( 98.90 %) | 1,320,046 ( 1.039 %) | 98.90 % |
Stock B | 0 | 582 | 0 | 0 |
Company contact information
Atossa Therapeutics, Inc.
107 Spring Street
98104, Seattle
+206 588 0256
http://www.atossatherapeutics.comSector
1st Jan change | Capi. | |
---|---|---|
+38.65% | 39.1B | |
-8.62% | 38.76B | |
+26.95% | 31.24B | |
+10.74% | 25.9B | |
-13.50% | 25.8B | |
+44.87% | 14.06B | |
+34.36% | 13.12B | |
-7.14% | 11.32B | |
-12.61% | 10.68B |
- Stock Market
- Equities
- ATOS Stock
- Stock
- Company Atossa Genetics Inc